Progress in Current Non-Viral Carriers for Gene Delivery
- Authors: Yoko Shoji Moskowitz, Daisuke Asai, Ami E.Iskandrian, Kota Kodama, Yoshiki Katayama, Hideki Nakashima6
-
View Affiliations Hide Affiliations6 Department of Microbiology, St. Marianna University School of Medicine, Japan, Japan
- Source: Frontiers in Medicinal Chemistry: Volume 5 , pp 81-97
- Publication Date: December 2010
- Language: English
Progress in Current Non-Viral Carriers for Gene Delivery, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9781608052080/chapter-4-1.gif
Since the viral vector for gene therapy has serious problems, including oncogenesity and other adverse effects, non-viral carriers have attracted a great deal of attention. However, the most critical issue of gene delivery by non-viral carriers is the low-expression efficiencies of the desired gene. In order to apply non-viral carriers for gene therapy in practical clinical usage, the improvement of transfection efficiency is a prerequisite. We will summarize the current progress of non-viral delivery systems for gene therapy. Especially, we will address the applications of cationic lipids (lipoplex) and cationic polymers (polyplex) in vivo. Furthermore, there have been reported a disease-site-specific delivery system which responds to highly activated cellular signals, which is called a drug delivery system based on responses cellular signal (D-RECS). We will also introduce the current progress of D-RECS gene delivery which is activated by HIV protease in only HIV-infected cells.
-
From This Site
/content/books/9781608052080.chapter-4dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
